



Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

August 28, 2024

SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2024-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences:

- Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-6, 2024, NY, NY:
 - Carmine Stengone, Contineum's President and CEO, will present on Wednesday, September 4, 2024, at 7:00 am ET.
- H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, NY, NY:
 - Carmine Stengone will present on Tuesday, September 10, 2024, at 2:30 pm ET.

The presentations will be available via webcast on the [Investors](#) section of Contineum's website and a replay will be available following conclusion of the presentations.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS) and PIPE-307, a selective inhibitor of the M1 receptor, in clinical development for relapse remitting MS. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024.

Contineum is headquartered in San Diego, CA. For more information, please visit www.contineum-tx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240828527257/en/): <https://www.businesswire.com/news/home/20240828527257/en/>

Company Contact:

Peter Slover
CFO

ir@contineum-tx.com

Source: Contineum Therapeutics, Inc.